Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Moving beyond epidermal growth factor receptor resistance in metastatic non-small cell lung cancer - a drug development perspective.

Critical reviews in oncology/hematology - 1 Mar 2021

Lai-Kwon Julia, Tiu Crescens, Pal Abhijit, Khurana Sachin, Minchom Anna

Abstract excerpt

Epidermal Growth Factor Receptor (EGFR) mutations are the most common targetable oncogenic driver mutation in metastatic non-small lung cancer (NSCLC). There have been significant advances in the management of metastatic EGFR-mutant NSCLC from the advent of first and second generation EGFR inhibitors to, more recently, the third-generation inhibitor osimertinib. Osimeritinib is now established as first-line...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Development

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 33482349
DOI: 10.1016/j.critrevonc.2021.103225

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Moving beyond epidermal growth factor receptor resistance in metastatic non-small cell lung cancer - a drug development perspective.PMID 33482349Read ↗

Current and Emerging Treatment Landscape of Common EGFR-Mutated Advanced Non-small Cell Lung Cancer.Semantic proximity Read ↗

Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance.Semantic proximity Read ↗

Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative GroupSemantic proximity Read ↗

Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung CancerSemantic proximity Read ↗

The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies.Semantic proximity Read ↗

New Strategies and Novel Combinations in EGFR TKI-Resistant Non-small Cell Lung Cancer.Semantic proximity Read ↗

Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?Semantic proximity Read ↗

Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience.Semantic proximity Read ↗

Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies.Semantic proximity Read ↗

Therapeutic approaches for T790M mutation positive non-small-cell lung cancer.Semantic proximity Read ↗

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.